Camurus ABCAMRF 81 EV-to-EBITDA is 31.57 as of Jul. 11, 2026. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $83.45 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 392 Biotechnology companies, Camurus AB ranks worse than 75.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Camurus AB's enterprise value is $3,003.4 Mil.
Camurus AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $95.1 Mil. Therefore, Camurus AB's EV-to-EBITDA for today is 31.57.
The historical rank and industry rank for Camurus AB's EV-to-EBITDA or its related term are showing as below:
CAMRF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -161.46 Med: -11.95 Max: 41021.92
Current: 33.48
During the past 13 years, the highest EV-to-EBITDA of Camurus AB was 41021.92. The lowest was -161.46. And the median was -11.95.
CAMRF's EV-to-EBITDA is ranked worse than 75.26% of 392
companies
in the Biotechnology industry
Industry Median: 12.935
vs CAMRF: 33.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Camurus AB (OTCPK:CAMRF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Camurus AB's share price for today is $60.00.
Camurus AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.205.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Camurus AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAMRF vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Camurus AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Camurus AB's EV-to-EBITDA falls into.
Camurus AB's current Enterprise Value is $3,003.4 Mil.
Camurus AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $95.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a EV-to-EBITDA of 31.57 as of Jul. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Camurus AB. According to the industry distribution chart, Camurus AB ranks #295 out of 392 companies in the Biotechnology industry, placing it in the top 75.3%.
Is Camurus AB's EV-to-EBITDA too high?
Camurus AB's current EV-to-EBITDA is 31.57. The Biotechnology industry median EV-to-EBITDA is 12.94. Camurus AB's value of 31.57 is 144.1% above this industry median. Based on the distribution chart, Camurus AB ranks #295 out of 392 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #295 out of 392 companies for EV-to-EBITDA. This places Camurus AB in the lower half of its industry. The industry median EV-to-EBITDA is 12.94. Camurus AB's value of 31.57 is 144.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.94, based on 392 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current EV-to-EBITDA of 31.57 is 144.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Camurus AB. For the Biotechnology industry, the median EV-to-EBITDA is 12.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current EV-to-EBITDA is 31.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.45, compared to a current price of $60.00 — trading 28.1% below its estimated fair value. The current EV-to-EBITDA is 31.57 and 144.1% above the Biotechnology industry median of 12.94. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Camurus AB (CAMRF), the current EV-to-EBITDA is 31.57 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $60.00 is trading 28.1% below its estimated GF Value™ of $83.45.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
EV-to-EBITDA: 31.57
GF Value™: $83.45 vs. price of $60.00 (28.1% below fair value)
Industry Position: 144.1% above the Biotechnology median (#295 of 392)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
